Description: Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
Home Page: www.captortherapeutics.com
ul. Dunska 11
Wroclaw,
54-427
Poland
Phone:
48 53 786 9089
Officers
| Name | Title |
|---|---|
| Dr. Thomas Shepherd Ph.D. | CEO & Pres of the Management Board |
| Mr. Sylvain Cottens | Co-Founder & Sr. VP of Chemistry |
| Mr. Radoslaw Krawczyk | Member of the Management Board & Chief Financial Officer |
| Mr. Michal Walczak | Member of Management Board & Chief Scientific Officer |
Exchange: WAR
Country: PL
Currency: Polish złoty (zł)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.9297 |
| Price-to-Sales TTM: | 150.7967 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 98 |